Olema Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−12.65%
vs ±30.4% implied · ×0.42
shaded = implied · ▲▼ = realized
Olema Pharmaceuticals has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
Olema Pharmaceuticals, Inc.
7.01
SentenceUnder the terms of the Aurigene Agreement, Aurigene provides to us an exclusive license to its portfolio of novel small molecule inhibitors of the target.
OLMA 10-Kaccession 0001193125-26-107169
SentenceWe successfully identified KAT6 as a novel target and entered into a collaboration with Aurigene Oncology in 2022, which led to the discovery and development of OP-3136.
OLMA 10-Kaccession 0001193125-26-107169
SentenceOn October 17, 2024, we signed an out-license of our de-prioritized TRPM4 targeted research program to Black Shadow Therapeutics LLC in exchange for potential single-digit royalties on world-wide net sales should a product be approved by regulatory authorities.
OLMA 10-Kaccession 0001193125-26-107169
Linked news
Expected move
No implied move.